@article{932ef636bcc949e4813ee578f7671472,
title = "Association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine",
keywords = "Clozapine, Depression, Distress, Schizophrenia, Treatment-resistant schizophrenia",
author = "Masaru Tsukahara and Ryuhei So and Nobuyuki Nomura and Kohei Kitagawa and Yuya Mizuno and Fuminari Misawa and Masafumi Kodama and Hiroyuki Uchida and Masaru Mimura and Hiroyoshi Takeuchi",
note = "Funding Information: Dr. Mimura has received grants from Daiichi Sankyo, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Shionogi, Takeda, and Tsumura; and speaker's fees from Bayer, Daiichi Sankyo, Eisai, Eli Lilly, Fujifilm RI Pharma, Hisamitsu, Janssen, Kyowa, Mochida, MSD, Mylan EPD, Nihon Mediphysics, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka, Pfizer, Santen, Shire Japan, Sumitomo Dainippon Pharma, Takeda, Tsumura, and Yoshitomiyakuhin. Funding Information: Dr. Mizuno has been supported by fellowship grants from Canon Foundation in Europe, Japan Society for the Promotion of Science, Astellas Foundation for Research on Metabolic Disorders, Japanese Society of Clinical Neuropsychopharmacology, and Mochida Memorial Foundation for Medical and Pharmaceutical Research; has received manuscript fees from Sumitomo Dainippon Pharma; and has received consultant fees from Signant Health, MedAvante-ProPhase and VeraSci. Funding Information: Dr. Takeuchi has grants from Daiichi Sankyo and Novartis Pharma; speaker's fees from EA Pharma, Kyowa, Janssen, Lundbeck, Meiji Seika Pharma, Mochida, Otsuka, Sumitomo Dainippon Pharma, Takeda, and Yoshitomiyakuhin; and advisory board fees from Janssen, Mitsubishi Tanabe Pharma, and Sumitomo Dainippon Pharma. ",
year = "2022",
month = feb,
doi = "10.1016/j.schres.2022.01.002",
language = "English",
volume = "240",
pages = "228--230",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
}
